Acurx Pharmaceuticals (ACXP) investor relations material

Executive summary

• Advanced ibezapolstat clinical program for both acute and recurrent CDI, aiming to establish it as a single-agent standard of care, supported by strong phase II results and new pilot trials.

• Recent FDA guidance may allow for a single pivotal trial for acute CDI, potentially accelerating regulatory timelines.

• Expanded intellectual property portfolio with new patents in the US, Korea, and internationally, extending protection for ibezapolstat and DNA pol IIIC inhibitors to 2039 and beyond.

• No product revenue to date; operations funded through equity offerings, including a registered direct offering and private placement in April 2026.

• Presented preclinical data showing DNA pol IIIC inhibitors preserve the gut microbiome and demonstrate systemic antibacterial activity.

Financial highlights

• Ended Q1 2026 with $9.3 million in cash, up from $7.6 million at year-end 2025; working capital was $7.0 million.

• Raised $3.1 million in gross proceeds during the quarter via equity line of credit.

• Research and development expenses were $0.3 million, down from $0.6 million year-over-year, mainly due to lower manufacturing and consulting costs.

• General and administrative expenses were $1.4 million, down from $1.6 million year-over-year, reflecting lower professional and legal fees.

• Reported a net loss of $1.7 million ($0.62 per diluted share), improved from $2.1 million ($2.15 per share) in Q1 2025.

Outlook and guidance

• Preparing for Phase 3 international pivotal trials for ibezapolstat in acute CDI, with potential for single pivotal trial approval per recent FDA guidance.

• Open-label pilot study in multiply-recurrent CDI to inform Phase 3 registration trial; FDA approval to be sought under Limited Population Pathway if successful.

• Management expects continued net losses and negative cash flows; additional capital will be required to sustain operations and advance clinical programs.

• Anticipates first patient enrollment in the rCDI trial around August 2026.

• Plans to seek further equity financing and grant funding, but availability and terms are uncertain.